ATE504653T1 - Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren - Google Patents
Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxvirenInfo
- Publication number
- ATE504653T1 ATE504653T1 AT03784104T AT03784104T ATE504653T1 AT E504653 T1 ATE504653 T1 AT E504653T1 AT 03784104 T AT03784104 T AT 03784104T AT 03784104 T AT03784104 T AT 03784104T AT E504653 T1 ATE504653 T1 AT E504653T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccinia virus
- avipoxviruses
- host range
- increasing
- cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 241000700618 Vaccinia virus Species 0.000 title abstract 4
- 238000001228 spectrum Methods 0.000 title 1
- 241000700663 Avipoxvirus Species 0.000 abstract 3
- 241000271566 Aves Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201189 | 2002-08-07 | ||
| PCT/EP2003/008359 WO2004015118A1 (en) | 2002-08-07 | 2003-07-29 | Vaccinia virus host range genes to increase the titer of avipoxviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE504653T1 true ATE504653T1 (de) | 2011-04-15 |
Family
ID=31502636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03784104T ATE504653T1 (de) | 2002-08-07 | 2003-07-29 | Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7473536B2 (https=) |
| EP (2) | EP2264178A1 (https=) |
| JP (1) | JP2005534326A (https=) |
| AT (1) | ATE504653T1 (https=) |
| AU (1) | AU2003255315A1 (https=) |
| CA (1) | CA2489301A1 (https=) |
| DE (1) | DE60336653D1 (https=) |
| WO (1) | WO2004015118A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| WO2004015118A1 (en) * | 2002-08-07 | 2004-02-19 | Bavarian Nordic A/S | Vaccinia virus host range genes to increase the titer of avipoxviruses |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| DK1536015T3 (da) * | 2003-11-24 | 2008-02-18 | Bavarian Nordic As | Promotorer til ekspression i modificeret vacciniavirus Ankara |
| ES2315096B1 (es) * | 2006-05-13 | 2009-12-30 | Consejo Superior De Investigaciones Cientificas | Vectores en los que se inserta el gen c7l y uso de los mismos en la fabricacion de vacunas y de composiciones para terapia genica. |
| CA2670804A1 (en) * | 2006-05-19 | 2007-11-29 | Sanofi Pasteur Inc. | Immunological composition |
| EP2424999A1 (en) | 2009-04-30 | 2012-03-07 | Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) | Modified immunization vectors |
| US20140093556A1 (en) | 2011-01-28 | 2014-04-03 | Sanofi Pasteur Sa | Immunological Compositions Against HIV |
| WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
| RS57290B1 (sr) * | 2013-11-01 | 2018-08-31 | Sementis Ltd | Proizvodnja virusnih vektora |
| EP3833367A4 (en) | 2018-08-08 | 2022-05-11 | Arizona Board of Regents on behalf of Arizona State University | Method for improved poxvirus yields |
| US20240309335A1 (en) * | 2021-06-30 | 2024-09-19 | Repli-Tech Co., Ltd. | Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| AU570940B2 (en) | 1982-11-30 | 1988-03-31 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for producing poxvirus recombinants for expression offoreign genes |
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| DE69233158T2 (de) * | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| MY150893A (en) | 1996-09-24 | 2014-03-14 | Bavarian Nordic As | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
| US6004777A (en) * | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6294176B1 (en) * | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
| FR2811766B1 (fr) | 2000-07-13 | 2002-09-27 | Tabacs & Allumettes Ind | Procede de caracterisation de la compacite d'objets tels que des cigarettes ou des filtres |
| AU2002246829A1 (en) * | 2000-12-22 | 2002-07-30 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health A | Methods to control the host range of retroviral vectors |
| WO2004015118A1 (en) * | 2002-08-07 | 2004-02-19 | Bavarian Nordic A/S | Vaccinia virus host range genes to increase the titer of avipoxviruses |
-
2003
- 2003-07-29 WO PCT/EP2003/008359 patent/WO2004015118A1/en not_active Ceased
- 2003-07-29 US US10/524,043 patent/US7473536B2/en not_active Expired - Fee Related
- 2003-07-29 EP EP10008652A patent/EP2264178A1/en not_active Withdrawn
- 2003-07-29 EP EP03784104A patent/EP1529113B1/en not_active Expired - Lifetime
- 2003-07-29 JP JP2004526814A patent/JP2005534326A/ja active Pending
- 2003-07-29 AU AU2003255315A patent/AU2003255315A1/en not_active Abandoned
- 2003-07-29 DE DE60336653T patent/DE60336653D1/de not_active Expired - Lifetime
- 2003-07-29 CA CA002489301A patent/CA2489301A1/en not_active Abandoned
- 2003-07-29 AT AT03784104T patent/ATE504653T1/de not_active IP Right Cessation
-
2008
- 2008-08-26 US US12/198,220 patent/US20090162935A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060039928A1 (en) | 2006-02-23 |
| EP1529113B1 (en) | 2011-04-06 |
| AU2003255315A1 (en) | 2004-02-25 |
| EP1529113A1 (en) | 2005-05-11 |
| US20090162935A1 (en) | 2009-06-25 |
| WO2004015118A1 (en) | 2004-02-19 |
| JP2005534326A (ja) | 2005-11-17 |
| CA2489301A1 (en) | 2004-02-19 |
| EP2264178A1 (en) | 2010-12-22 |
| US7473536B2 (en) | 2009-01-06 |
| DE60336653D1 (de) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE504653T1 (de) | Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren | |
| DE69737886D1 (de) | Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays | |
| BRPI0309631A8 (pt) | vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4 | |
| DK0702085T3 (da) | Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus | |
| WO2000003030A3 (en) | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species | |
| EA200201164A1 (ru) | Система трансфекции днк для получения инфекционного вируса гриппа | |
| CY1114598T1 (el) | Μεθοδος για την ενισχυση ενος ιου φυσαλιδωδους νοσου υπο συνθηκες ελευθερες ορου | |
| WO2005014806A3 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
| NO20032309D0 (no) | Modifisert variant av vaccinia ankaravirus | |
| WO2001039797A3 (en) | Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus | |
| DK0550553T3 (da) | Viral defekt vaccine fremstillet af en transkomplementerende cellelinie | |
| WO2003023040A3 (en) | Vaccinia virus mva-e3l-knockout-mutants and use thereof | |
| AU7411694A (en) | Viruses and their use as a vaccine against feline infectious peritonitis virus disease | |
| WO2003106641A3 (en) | IDENTIFICATION OF OLIGONUCLEOTIDES FOR CAPTURE, DETECTION AND QUANTIFICATION OF NUCLEIC ACIDS FROM HEPATITIS A VIRUS | |
| ATE412055T1 (de) | Impfstoffe gegen viren der marek krankheit (mdv) und varicella zoster virus. | |
| ATE507293T1 (de) | Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen | |
| DK1356062T3 (da) | Frembringelse af rekombinanter af kunstigt gærkromosom af human cytomegalovirus | |
| IL164179A0 (en) | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter | |
| MX2007009628A (es) | Virus de acido ribonucleico en replicacion como vacunas. | |
| ATE362538T1 (de) | Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen | |
| JP2005534326A5 (https=) | ||
| EA200601218A1 (ru) | Респираторно-синцитиальный вирус с перекрёстно компенсированным геномным дефицитом | |
| ATE500338T1 (de) | Verwendung des adenoviralen e2-late-promotors | |
| WO2007038316A3 (en) | Human cytomegalovirus latency promoting genes, related virus variants and methods of use | |
| ATE557091T1 (de) | Moleküle von hdv-nukleinsäuren, ihre fragmente und anwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |